Structural Determinants of G-protein α Subunit Selectivity by Regulator of G-protein Signaling 2 (RGS2) by Kimple, Adam J. et al.
Structural Determinants of G-protein  Subunit Selectivity by
Regulator of G-protein Signaling 2 (RGS2)*□S
Received for publication, February 27, 2009, and in revised form, May 24, 2009 Published, JBC Papers in Press, May 28, 2009, DOI 10.1074/jbc.M109.024711
Adam J. Kimple‡, Meera Soundararajan§, Stephanie Q. Hutsell¶, Annette K. Roos§, Daniel J. Urban‡, Vincent Setola‡,
Brenda R. S. Temple¶**, Bryan L. Roth‡, Stefan Knapp§‡‡, Francis S. Willard‡1,2, and David P. Siderovski‡§§1,3
From the Departments of ‡Pharmacology and ¶Biochemistry and Biophysics, National Institute of Mental Health Psychoactive
Drug Screening Program, §§Lineberger Comprehensive Cancer Center, and **R.L. Juliano Structural Bioinformatics Core Facility,
University of North Carolina, Chapel Hill, North Carolina 27599 and the §Structural Genomics Consortium and ‡‡Department of
Clinical Pharmacology, Oxford University, Oxford OX3 7DQ, United Kingdom
“Regulator of G-protein signaling” (RGS) proteins facilitate the
termination of G protein-coupled receptor (GPCR) signaling via
their ability to increase the intrinsic GTP hydrolysis rate of G
subunits (known as GTPase-accelerating protein or “GAP” activ-
ity). RGS2 is unique in its in vitro potency and selectivity as a GAP
forGq subunits.Asmanyvasoconstrictivehormones signal viaGq
heterotrimer-coupled receptors, it is perhaps not surprising that
RGS2-deficient mice exhibit constitutive hypertension. However,
to date the particular structural featureswithinRGS2determining
its selectivity for Gq over Gi/o substrates have not been com-
pletelycharacterized.Here,weexaminea trioofpointmutations to
RGS2 that elicits Gi-directed binding andGAP activities without
perturbing its association with Gq. Using x-ray crystallography,
we determined amodel of the triplemutantRGS2 in complexwith
a transition state mimetic form of Gi at 2.8-Å resolution. Struc-
tural comparison with unliganded, wild type RGS2 and of other
RGSdomain/G complexes highlighted the roles of these residues
inwild typeRGS2 thatweakenGi subunit association.Moreover,
these three amino acids are seen to be evolutionarily conserved
amongorganismswithmodern cardiovascular systems, suggesting
that RGS2 arose from the R4-subfamily of RGS proteins to have
specialized activity as a potent and selective Gq GAP that modu-
lates cardiovascular function.
G protein-coupled receptors (GPCRs)4 form an interface
between extracellular and intracellular physiology, as they con-
vert hormonal signals into changes in intracellular metabolism
and ultimately cell phenotype and function (1–3). GPCRs are
coupled to their underlying second messenger systems by het-
erotrimeric guanine nucleotide-binding protein (“G-proteins”)
composed of three subunits: G, G, and G. Four general
classes of G subunits have been defined based on functional
couplings (in theGTP-bound state) to various effector proteins.
Gs subfamily G subunits are stimulatory to membrane-bound
adenylyl cyclases that generate the second messenger 3,5-cyclic
adenosine monophosphate (cAMP); conversely, Gi subfamily G
subunits are generally inhibitory to adenylyl cyclases (4). G12/13
subfamilyG subunits activate the smallG-proteinRhoAthrough
stimulation of the GEF subfamily of RGS proteins, namely p115-
RhoGEF, LARG, andPDZ-RhoGEF (5).Gq subfamilyG subunits
are potent activators of phospholipase-C enzymes that generate
the second messengers diacylglycerol and inositol triphosphate
(6);more recently, two additional Gq effector proteins have been
described: the receptor kinase GRK2 and the RhoA nucleotide
exchange factor p63RhoGEF (7, 8).
The duration of GPCR signaling is controlled by the time G
remains bound to GTP before its hydrolysis to GDP. RGS pro-
teins are key modulators of GPCR signaling by virtue of their
ability to accelerate the intrinsic GTP hydrolysis activity of G
subunits (reviewed in Refs. 9 and 10). RGS2/G0S8, one of the
first mammalian RGS proteins identified (11) and member of
the R4-subfamily (10), has a critical role in the maintenance of
normostatic blood pressure both in mouse models (12, 13) and
in humans (14, 15); additionally, Rgs2-deficient mice exhibit
impaired aggression and increased anxiety (16, 17), behavioral
phenotypes with potential human clinical correlates (18, 19).
Although many RGS proteins are promiscuous and thus act
on multiple G substrates in vitro (e.g. Ref. 20), RGS2 exhibits
exquisite specificity for Gq in biochemical binding assays and
single turnover GTPase acceleration assays (20, 21). Consistent
with this in vitro selectivity,5 mice deficient in RGS2 uniquely
exhibit constitutive hypertension and prolonged responses to
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vasoconstrictors, as would be expected upon loss of a potent
negative regulator of Gq that mediates signaling from various
vasoconstrictive hormones such as angiotensin II, endothelin,
thrombin, norepinephrine, and vasopressin (22). In addition,
RGS2-deficient mice respond to sustained pressure overload
with an accelerated time course of maladaptive cardiac remod-
eling (23), a pathophysiological response that evokes myocar-
dial hypertrophy known to be critically dependent on Gq sig-
naling (24, 25).
To gain insight into the structural basis of the unique G
substrate selectivity exhibited by RGS2, a series of point
mutants in RGS2 were evaluated that enable this protein to
bind and accelerate GTP hydrolysis by Gi; we subsequently
delineated the structural determinants of the Gi/mutant
RGS2 interaction using x-ray crystallography. Three key posi-
tions, first identified by Heximer and colleagues (21) and high-
lighted in our structural studies as key determinants of RGS2
substrate selection, were also found to be conserved through-
out the evolution of the RGS2 protein in amanner suggestive of
specialization toward cardiovascular signaling modulation.
EXPERIMENTAL PROCEDURES
Chemicals and AssayMaterials—Unless otherwise noted, all
chemicals were the highest grade available from Sigma or
Fisher Scientific (Pittsburgh, PA).
Protein Expression and Purification—Using ligation-inde-
pendent cloning, DNA encoding human RGS2 (Lys71–His209),
fused to either hexahistidine alone (His6) or to His6-tagged
enhanced yellow fluorescent protein (YFP), was hybridized into
a Novagen (San Diego, CA) pET vector-based prokaryotic
expression construct as previously described (26, 27). Point
mutations corresponding to Cys106 to serine (C106S), Asn184 to
aspartate (N184D), Arg188 to glutamate (R188E), and Glu191 to
lysine (E191K) were made using QuikChange site-directed
mutagenesis (Stratagene, La Jolla, CA). For expression of hexa-
histidine- and His6-YFP fusion RGS2 constructs, BL21(DE3)
Escherichia coli were grown to an A600 nm of 0.7–0.8 at 37 °C
before induction with 0.5 mM isopropyl -D-thiogalactopyran-
oside. After culturing for 14–16 h at 20 °C, cells were pelleted
by centrifugation and frozen at 80 °C. Bacterial pellets were
then resuspended in N1 buffer (50 mMHEPES, pH 8.0, 400 mM
NaCl, 30mM imidazole, 5% (w/v) glycerol) and lysis of bacterial
slurry was performed using an Emulsiflex (Avestin, Ottawa,
Canada) according to the manufacturer’s instructions. Cellular
lysates were clarified by centrifugation at 100,000  g for 30
min at 4 °C. The supernatant was applied to a Ni2 chelating
fast protein liquid chromatography column (FF HisTrap; GE
Healthcare, Piscataway, NJ), washed with 7 column volumes of
N1 buffer then 3 column volumes of N1 buffer containing an
additional 30 mM imidazole before elution of recombinant
RGS2 protein with N1 buffer containing 300 mM imidazole.
His6-tagged RGS2 protein was cleaved with tobacco etch virus
protease overnight at 4 °C and dialyzed into N1 buffer contain-
ing 5 mM dithiothreitol. To separate residual His6-RGS2 from
untagged, cleaved RGS2, the protein was passed over a second
Ni2-chelating fast protein liquid chromatography column.
The flow-through was pooled, concentrated to final volume of
5 ml, and resolved using a calibrated 150-ml size exclusion
column (Sephacryl S200; GE Healthcare) using S200 buffer (10
mMHEPES pH 8.0, 300mMNaCl, 5mMdithiothreitol, 5% (w/v)
glycerol). Fractions containing monodisperse protein were
then pooled and concentrated to 500 M, as determined
by A280 nm measurements upon denaturation in 8 M guanidine
hydrochloride. Concentration was calculated based on the
predicted extinction coefficient (ProtParam, Swiss Institute for
Bioinformatics). Additional details regarding protein purifica-
tion for crystallography can be found online at the SGCOxford
website. Human RGS16 constructs, C-terminal biotinylated
Gi1, N-terminal deleted (N30) Gi1, CFP-Gi1, and Gi3
were purified exactly as previously described (20, 28, 29).
Single Turnover GTPase Assays—Single turnover [-32P]GTP
hydrolysis assays were conducted using recombinant Gi1 and
various concentrations of RGS proteins as previously described
(20). Briefly, 100 nMGi1 in reaction buffer (50mMTris pH 7.5,
0.05%C12E10, 1mMdithiothreitol, 10mMEDTA, 100mMNaCl,
and 5 g/ml bovine serum albumin) was incubated for 10 min
at 30 °Cwith 1 106 cpm (2nM) of [-32P]GTP (specific activity
of 6500 dpm/Ci). The reaction was then chilled on ice for 5min
prior to the addition of 10 mM MgCl2 and 100 M unlabeled
GTPS (final concentration) with or without added RGS pro-
tein. Reactions were kept on ice and 100-l aliquots were taken
at the indicated time points, quenched in 900 l of charcoal
slurry, and centrifuged before 600-l aliquots of supernatant
were counted via liquid scintillation.
Surface Plasmon Resonance—Optical detection of protein-
protein interactions by surface plasmon resonance (SPR) was
performed using a Biacore 3000 (GEHealthcare) exactly as pre-
viously described (20, 29, 30).
Förster Resonance Energy Transfer (FRET)-based Binding
Assays—Förster resonance energy transferwas used tomeasure
binding between Gi1 and the triple point mutant RGS2
(C106S,N184D,E191K) as previously described (26, 28). In
brief, FRET between recombinant Gi1-CFP and YFP-
RGS2(C106S,N184D,E191K) proteins was measured using a
SpectraMax Gemini fluorescence reader (Molecular Devices,
Sunnyvale,CA)using anexcitationwavelengthof 433nm(455nm
cutoff) and emission scans from 470 to 535 nm at 2-nm intervals.
Structure Determination—Purified G and RGS2(C106S,
N184D,E191K) proteins were mixed at a molar ratio of 1:1.5
and incubated at 4 °C for 20 min. The sample was passed
through an S200 gel filtration column pre-equilibrated with 25
mM HEPES, pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM dithio-
threitol, 100 M AlCl3, 20 mM sodium fluoride, and 100 M
GDP. Protein fractions that eluted as a complex were identi-
fied using SDS-PAGE and the fractions were pooled and con-
centrated to 23 mg/ml prior to crystallization condition
screens using a 150-nl drop volume with an TTP Labtech
Mosquito nanoliter liquid-handling system. The crystal of
the RGS2(C106S,N184D,E191K)-Gi3 complex used for
data collection was crystallized by vapor diffusion in sitting
drops of 400 nl of protein and 200 nl of reservoir solution
containing 0.1 M HEPES, pH 7.5, and 2 M ammonium sulfate
(TTP Labtech Mosquito).
After cryoprotection in a solution of 2 M ammonium sulfate,
0.1 M HEPES, pH 7.5, and 20% (w/v) D-glucose, crystals were
flash cooled in liquid nitrogen. A complete data set was col-
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lected at 100 K on a Rigaku/MSC FR-E rotating anode x-ray
generator equipped with an R-AXISHTC image plate detector.
Diffraction images were evaluated with MOSFLM (31), and
data were scaled using SCALA (32). The crystal belonged to the
space group P3221 with unit cell dimensions a  114.54 Å, b 
114.54 Å, and c  99.33 Å. A molecular replacement solution
was found in this space group using PHASER (33) with the
RGS10/Gi3 complex (PDB code 2IHB) as the search model.
The RGS2 coordinates from PDB code 2AF0 were superim-
posed onto the RGS10 coordinates of the RGS10/Gi3 posi-
tioned complex and rigid body refinement into the electron
density was performed using REFMAC5 (34). Difference den-
sity in the GDP binding site was modeled using the higher res-
olution structure of Gi3 in the RGS8/Gi3 complex (PDB code
2ODE) with one molecule of GDP, a tetrafluoroaluminate ion,
and amagnesium ion coordinated by two additional watermol-
ecules. Several rounds of manual rebuilding in COOT (35) and
restrained refinement with REFMAC5 (34), using Translation/
Libration/Screw (TLS) groups calculated with TLSMD (36),
resulted in the final structural model described in Table S1.
Coordinates of the RGS2(C106S,N184D,E191K)-Gi3 complex
were deposited in the Protein Data Bank with entry code of
2V4Z.
Cellular cAMPSignalingAssays—HEK293T cells were trans-
fected using Lipofectamine 2000 (Invitrogen) in 6-well dishes
with 4 g of total DNA including pGloSensorTM-20F cAMP
biosensor plasmid (Promega Corp., Madison WI), dopamine
D2 receptor, and empty vector, HA-RGS2(WT), or HA-
RGS2(C106S,N184D,E191K). The RGS2 expression vectors
encoded solely the RGS domain (amino acid Lys71–His209; with
an N-terminal HA epitope tag) to avoid the influence of non-
RGS domain regions on adenylyl cyclase function (e.g. Ref. 37).
Twenty-four hours post-transfection, cells were re-plated on
poly-D-lysine-treated, clear-bottom, white 96-well plates at a
density of 60,000 cells/well. Forty-eight hours post-transfec-
tion, culturemediumwas aspirated and cells were washed once
with assay medium (Dulbecco’s modified Eagle’s medium with
10% fetal bovine serum (without phenol), 15 mM HEPES, pH
7.4) before being incubated for 2 h with 40 l/well of equilibra-
tion medium (assay medium with 4% GloSensorTM substrate).
After 2 h, 6.6l of 6 final concentration of quinpirole (diluted
in 10 M forskolin-containing assay medium) was added to
FIGURE 1. Gi1 and Gq selectivity of wild type RGS2 versus RGS2 point mutants profiled by SPR. Gi1-biotin (left) or His6-Gq (right) were immobilized on
sensor surfaces for binding analyses of the indicated RGS2 protein analytes (3 M final concentration). Analyte injections were performed at a flow rate of 20
l/min for 600 s (start time  0 s) over surfaces of G subunits in the inactive state (GDP-bound; dashed lines) or in the transition state for GTP hydrolysis (i.e.
GDPAlF4
-bound; solid lines). Legend in panel A also applies to sensorgrams of panel B.
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each well and allowed to incubate
for 10 min before GloSensor emis-
sion was read on aMicroBeta Plate
Counter (PerkinElmer). Before
plotting, luminescence counts
were normalized to 100% maximal
response for each condition to
account for variability in Glo-
Sensor expression, transfection
efficiency, and the exact number
of cells per well.
RESULTS AND DISCUSSION
Evaluating Point Mutations to
RGS2 That Facilitate Interaction
with Gi1—RGS2 is the only mem-
ber of the R4-subfamily known to
bind specifically to Gq and not to
Gi/o heterotrimeric G-protein
subunits in vitro (20, 21). Three
amino acidswithinRGS2were iden-
tified by Heximer and colleagues
(21) as potential selectivity determi-
nants in studies of Go-directed
GAP activity by RGS domain chi-
mera derived from RGS2 and RGS4
sequences: namely, cysteine 106,
asparagine 184, and glutamate 191.
In the present study, we mutated
these three amino acids to the
highly conserved corresponding
amino acids in R4-subfamily mem-
bers (Cys106 to serine, Asn184 to
aspartate, and Glu191 to lysine; sup-
plementary Fig. S1) to identify their
respective contributions to G sub-
strate specificity.
RGS2 proteins containing these
point mutations, either singly, in
tandem, or all three together, were
expressed in E. coli and purified to
homogeneity (Fig. S2). SPR spec-
troscopy was used (e.g. Fig. 1) to
assess if any individual mutation, or
combination of point mutations,
was capable of changing the selec-
tivity of RGS2. All mutants retained
wild type binding toward Gq (e.g.
Fig. 1B). Single mutations to RGS2
(C106S, N184D, or E191K) did not
enhance binding to Gi1 and only
minimal enhancements to binding
were observed with the C106S,
N184D, C106S,N191D, and E191K,
N184D double mutants (e.g. Fig.
1A); in contrast, the triple mutant
RGS2 exhibited a dramatic increase
in Gi1 binding versus wild type
FIGURE 2. Quantitation of RGS2 binding to Gi1. SPR was performed as described in the legend to Fig. 1, with the
concentration of the RGS2 analyte titrated from 1 nM to 50 M. Sensorgrams were subsequently used in equilibrium
saturation binding analyses to determine RGS2/Gi1 interaction binding affinities. Dissociation constants (KD values)
were estimated to be 21.1 (95% CI, 11.6–30.7 M), 5.3 (95% CI 3.1–7.5 M), and 8.6 (95% CI 5.4–11.9 M) for the
double mutants RGS2(C106S,E191K), RGS2(C106S,N184D), RGS2(N184D,E191K), respectively, and determined to be
1.25 (95% CI, 1.0–1.6 M) for the triple mutant RGS2(C106S,N184D,E191K). A KD value for the wild type RGS2/Gi1
interaction could not be estimated because saturation was not obtained at concentrations tested.
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RGS2. Although the magnitude of binding of the RGS2 double
mutants was significantly less than that observedwith the triple
mutant, binding isotherms were nonetheless generated for all
double mutants along with the triple mutant by injecting
increasing concentrations of RGS2 protein over the
Gi1GDPAlF4 surface. Using equilibrium binding analyses
(Fig. 2), dissociation constants (KD values) for the RGS2/
Gi1GDPAlF4 interaction were estimated to be 5.3, 8.6,
and 21.1 M, for C106S,N184D, E191K,N184D, and
C106S,E191K, respectively, whereas the KD value was deter-
mined to be 1.25 M for the RGS2(C106S,N184D,E191K) triple
mutant. Dissociation constants derived for the RGS2 double
mutants are likely underestimated given an inability to attain
saturating concentrations of these particular RGS2 analytes
and thereby attain maximal binding (Bmax).
To determine whether the enhanced affinity of the RGS2
triple mutant was the result of improvements to a canonical
RGS domain/G interaction interface, a highly conserved, sur-
face-exposed arginine within this canonical interface (Arg188 in
the VIII helix; Fig. S1) was mutated to glutamic acid. As has
been shown for other RGS proteins (38), this single charge-
reversal point mutation (R188E) on the G-binding surface of
the RGS2 triple mutant abolished binding to Gi1GDPAlF4
(Fig. 2B, bottom panel).
To quantify any difference in the ability of the
RGS2(C106S,N184D,E191K) triple mutant to bind Gq,
increasing concentrations of wild type RGS2 and RGS2 triple
mutant proteins were separately injected over an immobilized
GqGDPAlF4 surface (Fig. 3). Dissociation constants were
determined to be 55 nM (95% confidence interval (CI) of 23–87
nM) and 17 nM (95% CI, 9–27 nM) for wild type RGS2- and
RGS2(C106S,N184D,E191K)-bound Gq, respectively.
To confirm these SPR-derived results with an orthogonal
technique of assessing the RGS domain/G interaction, FRET
measurements were performed using a YFP-RGS2 (C106S,
N184D,E191K)/Gi1-CFP pair, similar to the RGS4/Gi1 inter-
action FRET assay we have previously described (28). In the
presence of GDP, aluminum tetrafluoride, and Mg2 (“AMF”),
binding betweenRGSprotein and theG subunit is observed as
an increase in YFP emission and decrease in CFP emission; in
the presence of GDP alone, no binding is observed as
expected (28, 39) and so the ratio of YFP to CFP emission
remains low. The relative affinities of wild type RGS2,
RGS16, and RGS2 triple mutant were assessed by using this
FRET binding assay in a competitive manner: unlabeled RGS
protein was added in increasing amounts to a fixed concen-
tration of YFP-RGS2(C106S,N184D,E191K) and Gi1-CFP
proteins. As expected, only unlabeled RGS2(C106S,N184D,
E191K) and RGS16 proteins were able to inhibit the binding
of the RGS2(C106S,N184D,E191K)/Gi1 FRET pair (Fig. 4),
with observed IC50 values of 526 nM (95% CI, 236–1171 nM)
and 115 nM (78–168 nM), respectively. At no concentration
tested was wild type RGS2 able to inhibit binding of the
RGS2(C106S,N184D,E191K)/Gi1 FRET pair (Fig. 4B), con-
sistent with the lack of affinity between wild type RGS2 and
Gi subunits seen in our present SPR analyses and previously
published studies (20, 21).
Determinants of RGS2 GAP Activity on Gi1 in Vitro—Using
SPR and FRET, we demonstrated that all three point mutations
were required to facilitate high affinity binding of RGS2 toGi1.
To determine whether this enhanced binding affected the abil-
ity of RGS2 to accelerateGTPhydrolysis byGi1, we performed
single turnover GTPase assays with both wild type and triple
mutant RGS2 proteins (Fig. 5). At
no concentration tested was wild
type RGS2 capable of increasing
GTP hydrolysis over the intrinsic
GTP hydrolysis rate of Gi1 (Fig.
5A). In contrast, a substoichiomet-
ric amount of RGS16 (a knownGi1
GAP; Ref. 40) was able to accelerate
Gi1 GTPase activity; complete
hydrolysis of bound GTP was
observed in less than 15 s at 0 °C.
Unlike wild type RGS2, the
RGS2(C106S,N184D,E191K) triple
mutant was able to increase the rate
of Gi1 GTP hydrolysis in a dose-
dependent manner (Fig. 5B); how-
ever, adding the R188E mutation to
FIGURE 3. Quantification of RGS2 binding to Gq. SPR was performed as
described in the legend to Fig. 1, using an immobilized His6-GqGDPAlF4
surface and RGS2 analyte concentrations from 0.5 to 1000 nM. Using equilib-
rium saturation binding analyses, RGS2/Gq dissociation constants were
determined to be 55 nM (95% CI, 23.4 – 86.9 nM) for wild type RGS2 and 17 nM
(95% CI, 8.7–27.0 nM) for the RGS2(C106S,N184D,E191K) triple mutant.
FIGURE 4. Competition FRET assays of the Gi1-CFP/YFP-RGS2(triple) interaction. A, the fusion pro-
teins YFP-RGS2(C106S,N184D,E191K) and Gi1-CFP interact in the presence of GDP and AlF4Mg
2 (“AMF”)
but not in the presence of GDP alone. This interaction can be inhibited by the addition of unlabeled
RGS2(C106S,N184D,E191K) “triple” mutant protein (IC50 value of 526 nM; 95% CI, 236 –1171 nM), but not by the
addition of buffer alone. B, the addition of unlabeled wild type RGS2 to the Gi1-CFP/YFP-RGS2(triple mutant)
FRET pair does not result in a decrease in FRET; however, the addition of RGS16 (known to have affinity for Gi1
(20) competitively inhibits binding (IC50 value of 115 nM; 95% CI, 78 –168 nM).
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the triple mutant resulted in a com-
plete loss inGAP activity, consistent
with the loss of Gi1 binding
observed in SPR and FRET assays.
To further confirm that the mecha-
nism of action of the RGS2(C106S,
N184D,E191K) triple mutant in
increasing GTP hydrolysis by Gi1
was related to a canonical RGS
domain/G interaction and not the
inadvertant addition of a contami-
nating GTPase, we assessed the
effects of both RGS2(C106S,
N184D,E191K) and RGS16 proteins
on an RGS-insensitive Gi1 point
mutant: specifically, G183S in the
G switch I region (41). Neither
RGS2(C106S,N184D,E191K) nor
RGS16 proteins were able to
increase the intrinsic rate of GTP
hydrolysis exhibited by this RGS-in-
sensitive Gi1 (Fig. 5, C and D).
Determinants of RGS2 Activity
on Gi-coupled GPCR Signaling in
Cells—To validate in a cellular con-
text the change in G specificity ex-
hibited in vitro by the RGS2(C106S,
N184D,E191K) triple mutant, we
used an intracellular cAMP biosen-
sor to measure Gi heterotrimer-
mediated inhibition of forskolin-
stimulated cAMP production in
HEK293T expressing the Gi-cou-
pled D2 dopamine receptor along
with either wild type RGS2 or the
RGS2(C106S,N184D,E191K) mu-
tant. Upon treatment of transfected
cells with forskolin, a robust
increase in luminescence was observed from the cAMP sensor,
reflecting direct activation of adenylyl cyclase by forskolin (4);
upon administration of the dopamine D2/D3-receptor selec-
tive agonist, quinpirole, dose-dependent inhibition of this
cAMP production was observed.Wild type RGS2 had no effect
on the IC50 of quinpirole (Fig. 6). However, cellular expression
of the RGS2(C106S,N184D,E191K) triple mutant resulted in a
significantly higher IC50 for quinpirole (762 versus 18 nM for
empty vector; Fig. 6), indicating that the gain of Gi-directed
activity is readily apparent in a cellular context as well as in vitro
for the RGS2 triple mutant.
Structural Determinants of RGS2 Interaction with G
Subunits—To determine the structural basis for the G selec-
tivity of RGS2, we used x-ray crystallography to obtain a struc-
tural model of the RGS2 triple mutant bound to a Gi subunit.
A diffraction pattern data set was collected on a single crystal
containing a complex between the RGS2(C106S,N184D,
E191K) triple mutant and Gi3GDPAlF4 and was refined to
2.8-Å resolution (supplemental Table S1). The resultant struc-
tural model revealed canonical RGS domain/G interactions
FIGURE 5. The triple mutant RGS2(C106S,N184D,E191K), but not wild type RGS2, accelerates the GTP
hydrolysis rate of Gi1. A, increasing concentrations of wild type RGS2 (as indicated) are unable to accelerate
the GTP hydrolysis of 200 nM Gi1. Intrinsic GTP hydrolysis by isolated Gi1 (kobs) was measured at 0.0075 s
1
(95% CI 0.0055– 0.010 s1), whereas kobs values of 0.0076 (0.0055– 0.0097), 0.0066 (0.0054 – 0.0078), and 0.0086
(0.0069 – 0.010) s1 were observed upon the addition of 50, 2500, or 5000 nM wild type RGS2, respectively.
RGS16 is a potent GAP for Gi subunits (e.g. Ref. 20) and, at substoichiometic concentrations (50 nM), was found
to accelerate GTP hydrolysis by Gi1: kobs of at least 0.18 s
1 (an underestimate as the measurement is limited
by sampling time constraints). B, the triple mutant RGS2(C106S,N184D,E191K) was observed to accelerate GTP
hydrolysis by 200 nM Gi1 in a dose-dependent manner: kobs values of 0.0075 (0.0055– 0.0095), 0.0079 (0.0068 –
0.0089), and 0.028 (0.023– 0.032) s1 were observed upon the addition of 0, 10, and 50 nM RGS2(triple) protein,
respectively. Higher concentrations of RGS2(triple) protein (200, 500, 1000, and 5000 nM) led to GTPase rates of
at least 0.1– 0.2 s1 (again underestimated due to sampling time constraints). The triple mutant also containing
a fourth, loss-of-function point mutation (namely, RGS2(C106S,N184D,E191K,R188E)) was unable to accelerate GTP
hydrolysis by Gi1: with a kobs value of 0.0076 (0.0066–0.0086) s
1. C, the single point mutation to Gi1 (glycine 183
to serine, G183S (41)) renders Gi1 insensitive to the GAP activity of RGS proteins. The intrinsic hydrolysis rate of the
Gi1(G183S) mutant was determined to be 0.0053 (0.0037–0.0069) s
1. Upon addition of 200, 3000, or 5000 nM of
the RGS2(C106S,N184D,E191K) triple mutant, the kobs was found to be 0.0036 (0.0026–0.0046), 0.0042 (0.0060–
0.0078), and 0.0025 (0.00017–0.0048) s1, respectively; the kobs for GTP hydrolysis after addition of 200 nM RGS16
was observed to be 0.0064 (0.0052–0.0076) s1. D, the kobs values are plotted versus concentration of RGS protein to
demonstrate the dose-dependent increase in GAP activity upon the addition of RGS2(C106S,N184D,E191K) protein
to wild type Gi1, but not the RGS-insensitive Gi1(G183S) mutant.
FIGURE 6. The triple mutant RGS2(C106S,N184D,E191K), but not wild type
RGS2, inhibits dopamine D2-receptor influence on forskolin-stimulated
cAMP production. HEK293T cells were transiently co-transfected with expres-
sion vectors for the GloSensor cAMP biosensor and the Gi-coupled dopamine
D2-receptor with empty vector, wild type RGS2, or the RGS2(triple) mutant. Inhi-
bition of forskolin-stimulated cAMP production was determined after activation
of the D2 receptor with various concentrations of quinpirole as indicated. The
IC50 (95% CI) for quinpirole was determined to be 18 (12–26), 14 (9–22), and 762
(498–1170) nM in the presence of empty vector, wild type RGS2, and the triple
mutant, respectively. Inset, post-transfection cell lysates were immunoblotted
with anti-HA epitope tag antibody to confirm the equivalent overexpression of
HA-RGS2 and HA-RGS2(C106S,N184D,E191K) proteins.
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(20, 42), specifically, contacts
between the flexible switch regions
of Gi3 and the nine -helical bun-
dle formed by the RGS2 triple
mutant (Fig. 7).
One of the three mutation sites
within the RGS2 triple mutant,
aspartate 184, is observed to form a
double salt bridge (Fig. 8A and Fig.
S3) with the neighboring arginine
188, the latter being an VIII resi-
due completely conserved among
all other R4-subfamily RGS do-
mains (Fig. S1). Asparagine 184 of
wild type RGS2, located between
helix VII and VIII, is an aspartic
acid in all other R4-subfamily RGS
domains (Fig. S1). The additional
terminal oxygen present in the
aspartate side chain (and missing in
asparagine) normally allows two salt
bridges to be formed (Fig. 8A) with
the conserved VIII helix arginine
residue (e.g. Arg170 of RGS16,
Arg188 of RGS2). These salt bridges
are not consistently observed in all
unliganded RGS domain structures
(20); however, this double salt
bridge is present in all R4-subfamily
RGS domains complexedwithGi/o
subunits (Table S2), suggesting that
their formation is important for
making the RGS domain competent
to bind Gi/o subunits. The impor-
tance of this Arg-Asn side chain
interaction is supported by the loss
of Gi binding and Gi-directed
GAP activity when this VIII helix
arginine is mutated to glutamate
(Figs. 2 and 5). The significance of
this intramolecular interaction is
further supported by observations
that mutating the analogous VIII
helix arginine in RGS4 (Arg167) and
RGS12 (Arg821) results in loss of
Gi/o binding and Gi/o-directed
GAP activity (38, 43, 44). Although
Arg188 of RGS2 does not make any
critical contacts with Gi3 per se, it
has a critical role in orientingAsp184
(Fig. 8B) to form a conserved hydro-
gen bondwith themain chain amide
of a threonine residue in the G
switch I region (Thr182 of Gi (20,
42); Thr183 of Go (45)). In the
structure of wild type, uncomplexed
RGS2 (PDB code 2AF0; Ref. 20),
asparagine at this position (Asn184)
FIGURE 7. Overall structural features of the RGS2(C106S,N184D,E191K)-Gi3GDPAlF4
 complex. A, the
tertiary structure of Gi3 is composed of a Ras-like domain (red) and an all -helical domain (blue) and is present
in a transition-state mimetic form bound to a molecule of GDP (magenta) and tetrafluoroaluminate (AlF4
) ion
(gray/blue sticks). The three critical switch regions of G (numbered Sw I to Sw III) are colored cyan. All three switch
regions are engaged by the RGS2 RGS domain (yellow-green). Panel B represents the same structural model as in
panel A, but rotated to highlight contacts made by residues serine 106, aspartate 184, and lysine 191 of the
RGS2(C106S,N184D,E191K) triple mutant. This same orientation of the complex is presented in Fig. 8B.
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forms only a single hydrogen bond with terminal amine of
Arg188 and, rotated in this manner, the side chain cannot at the
same time form a hydrogen bond with the Thr182 backbone
(Fig. 8A and Table S2).
The aspartate substitution at position Asn184 is critical to
allow binding of RGS2 to Gi; however, this single substitution
alone is not sufficient to engender robust Gi binding (Fig. 1).
Ser106 is completely conserved among all R4-subfamily RGS
domains except RGS2, in which this position is a cysteine resi-
due (Fig. S1). Mutating Cys106 to serine was also necessary to
obtain high affinity binding to Gi subunits (Figs. 1 and 2);
whereas the Ser106 side chainwas not observed in the structural
model to make any critical contacts with Gi3, this residue is
tightly packed among other residues (Fig. 8B). The structure of
the RGS2(C106S,N184D,E191K)-Gi3 complex reveals that the
-carbon of Ser106 is closely juxtaposed with the backbone car-
bonyl and -hydroxyl of Thr182 within switch I of Gi3; addi-
tionally, the-carbon of Ser106 is 3.8Å from the terminal amine
of Lys210 within switch II of Gi3. In conjunction with the SPR
binding data, the observed tight packing of Ser106 within the
RGS2(C106S,N184D,E191K)-Gi3 complex suggests that the
Cys106 residue of wild type RGS2 prevents high affinity binding
to Gi subunits by steric blockade of interactions with switch I
and switch II of the G subunit.
Although amino acid positions 106 and 184 are completely
conserved among all R4-subfamily RGS domains except RGS2,
the specific amino acid at position 191 is conserved only in its
basic character, being either a lysine or an arginine in all
R4-subfamily RGS domains (Fig.
S1). In wild type RGS2, this position
is instead an acidic residue (gluta-
mate 191). In the structural data
derived from the RGS2(C106S,
N184D,E191K)-Gi3 complex, elec-
tron densitywas present only for the
-,-, and-carbons of themutated
Lys191; however, the final ordered
carbon atom was found to be only
5.1 Å from the hydroxyl oxygen of
Glu65 in the Ahelix of the Gi3 all-
helical domain. Electron density
was present to fit the C, C, C,
and C atoms of the Lys191 residue
(Fig. S3). The C and terminal
amine were modeled by superim-
posing a Lys over those parts of the
carbon atom chain that could be
placed with electron density, reveal-
ing that this basic side chain would
be less than 3.0 Å from the hydroxyl
oxygen of Gi3 Glu65 and thus
within hydrogen bonding distance.
It is possible that the high salt con-
centration necessary for crystalliza-
tion screened the electrostatic con-
tribution of this interaction away,
resulting in a partially disordered
side chain. In wild type RGS2, this
salt bridge would be lacking and this position instead would
create electrostatic repulsion between RGS2Glu191 and the all-
helical domain of Gi3. The importance of all-helical domain
contacts to RGS protein selectivity for G substrates has been
previously speculated for the retinal-specific proteins RGS9-1
and G-transducin (46); our present finding with RGS2 pro-
vides one of the first structural insights into these interactions.
These RGS domain/all-helical domain interactions, whereas
typically underappreciated when considering the structural
determinants of the RGS protein/G interaction interface (e.g.
Refs. 42 and cf. 20), may provide a unique point of interdiction
to exploit with selective RGS protein inhibitors.
Unique Determinants of RGS2 Gq Selectivity Are Conserved
among Species with Cardiovascular Systems—Current knowl-
edge of G selectivity suggests that R4-subfamily members, as
well as proteins from the more ancestral RZ-subfamily (e.g.
RGS17, -19, and -20), can act as GAPs for both Gi and Gq
subunits (20, 47), with the R4-protein RGS2 particularly
attuned to Gq over Gi. Given its uniqueG selectivity and its
specialized role in cardiovascular signal transduction, RGS2 is
likely to have arisen from the R4-subfamily in response to the
development of cardiovascular structures and function.
In evolutionary terms, Gq emerged as the harbinger of a
distinct and recognizable G subfamily in fungi, and Gq sub-
units are present in all metazoans including sponges (48, 49).
Although RZ-subfamily RGS proteins are represented within
the genomes of nematodes and arthropods (50), a distinct
R4-subfamily does not appear until the evolution of urochor-
FIGURE 8. Particular G selectivity determinants inferred from the structural model of the triple mutant
RGS2(C106S,N184D,E191K) bound to Gi3. A, illustration of the VII–VIII region of the RGS domain to
highlight the intramolecular interaction between the highly conserved VIII helix arginine (Arg188 of RGS2) and
position 184 (asparagine in wild type RGS2 and aspartate in the triple mutant). RGS2(C106S,N184D,E191K)
triple mutant (yellow-green; PDB code 2V4Z), unliganded wild type RGS2 (gray; PDB code 2AF0), and the
Gi1-bound RGS16 (dark green; PDB code 2IK8) were aligned by sequence and then structure (C atoms) using
the Align command with default align settings of MacPyMOL (DeLano Scientific, Palo Alto, CA), resulting in root
mean square deviations of 0.92 and 0.80 Å, respectively. The conserved Arg188 makes salt bridges with the
terminal oxygens of the Asp184 side chain in the RGS2(C106S,N184D,E191K) mutant and the analogous aspar-
ate side chain in RGS16; however, only one contact can be made between Arg188 and the Asn184 side chain of
wild type RGS2. Loss of the second salt bridge creates a torsion in the wild type RGS2 Asp184 residue, resulting
of the loss of the stabilizing hydrogen bond to Thr182 in switch I of the G subunit. B, critical contacts between
the three mutated positions of RGS2(C106S,N184D,E191K) (yellow-green) and its G binding partner (Ras-like
domain in red; all-helical domain in blue; switch regions in cyan; bound GDP in magenta). The modeled terminal
atoms of the Lys191 side chain (spheres) within RGS2(C106S,N184D,E191K) are in close enough proximity to
make a hydrogen bond with Glu65 of the G all-helical domain. Asp184 makes two hydrogen bonds with Arg188
and an additional bond with the backbone amine of the peptide bond connecting Thr181 and Thr182, both
located within switch I of G. Ser106 of the RGS2 triple mutant is tightly packed with the backbone carbonyl and
-hydroxyl of G Thr182, both being less than 3.9 Å from -carbon of Ser106. Additionally, the G switch II
residue Lys210 is 3.8 Å from the Ser106 -carbon.
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dates. The genome of the urochordate Ciona intestinalis (sea
squirt) encodes at least twoRGSproteins (Fig. 7), an ortholog of
the ancestral RZ-subfamily progenitor found in nematodes and
arthropods, as well as a newly divergent R4-subfamily member
(but not an RGS2 ortholog per se).With specialized tissues such
as a notochord, digestive tract, single chamber heart, and
gonads, C. intestinalis is commonly considered an excellent
modern representative of the precursor to higher vertebrates
(51, 52). Agnatha (jawless fish) such as the sea lamprey Petro-
myzonmarinus are considered themost primitive extantmem-
bers of early vertebrates (53) and represent the first vertebrate
to exhibit cardiac innervation (54). Although the P. marinus
cardiovascular system is more advanced than the open system
ofC. intestinalis, it is still considered primitive in that it lacks an
elastin-reinforced vasculature (55), coronary circulation, and a
pericardial-contained fourth chamber (conus or bulbus arteri-
osus) to dampen systolic oscillations in blood pressure (54).
Similar to C. intestinalis, the genome of P. marinus encodes at
least two RGS proteins, the ancestral RZ member and a single
R4member (Fig. 9); however, noRGS2-like protein has yet been
identified in this species.
As chordates evolved into the Gnathostomata (jawed verte-
brates), the cardiovascular system rapidly developed coronary
vessels, inhibitory vagal innervation, excitatory adrenergic
innervation, and responses to prostaglandins, nitric oxide, and
endothelin (56). This advance is marked in Danio rerio by the
addition of multiple R4 proteins, specifically including a Gq-
specific RGS2 protein (Fig. 9). This unique member of the
R4-subfamily, with cysteine, asparagine, and aspartate at the
three key specificity positions, is highly conserved in the extant
representatives of all subsequent evolutionary steps: amphibi-
ans (e.g. Xenopus laevis and Xenopus tropicalis), avians (e.g.
Gallus gallus) andmammals (Fig. 9); the three defining residues
are seen to be unique among all R4-subfamily members within
a given species (e.g. human R4 paralogs aligned in Fig. S1). Only
amphibians (X. laevis and X. tropicalis) do not contain all three
RGS2-defining amino acids (Fig. 9): whereas the RGS2 signa-
ture residue asparagine is present at position 184, serine (not
cysteine) is present at position 106, and aneutral glutamine (not
glutamate) is present at position 191. (Note that the latter glu-
tamine is not seen in RGS2, RGS4, nor RGS20 paralogs.) Even
though the conservation is not absolute in the amphibians, we
have shown that asparagine in position 184 is sufficient on its
own to significantly reduce Gi affinity (i.e. 20-fold; compare
KD of21M for theC106S,E191KRGS2doublemutant versus
KD of 1.25M for theC106S,N184D,E191K triplemutant in Fig.
2). In conclusion, the conservation of these three key residue
positions suggests that RGS2 has indeed evolved from the
R4-subfamily to be a specialized Gq GAP for the modern car-
diovascular system by acquiring particular residues at one or
more of three key positions that have been highlighted in our
mutagenesis/crystallography studies.
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